home / stock / atbpf / atbpf quote
Last: | $0.2156 |
---|---|
Change Percent: | 12.38% |
Open: | $0.1889 |
Close: | $0.2156 |
High: | $0.2452 |
Low: | $0.1889 |
Volume: | 33,935 |
Last Trade Date Time: | 04/08/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.2156 | $0.1889 | $0.2156 | $0.2452 | $0.1889 | 33,935 | 04-08-2024 |
$0.19 | $0.2263 | $0.19 | $0.2263 | $0.18865 | 22,355 | 04-05-2024 |
$0.2086 | $0.2 | $0.2086 | $0.225 | $0.2 | 115,129 | 04-04-2024 |
$0.19418 | $0.15 | $0.19418 | $0.2146 | $0.15 | 151,112 | 04-03-2024 |
$0.1358 | $0.1113 | $0.1358 | $0.14 | $0.1113 | 46,700 | 04-02-2024 |
$0.1153 | $0.165 | $0.1153 | $0.1732 | $0.1113 | 181,162 | 04-01-2024 |
$0.3345 | $0.3345 | $0.3345 | $0.3345 | $0.3345 | 940 | 03-29-2024 |
$0.3345 | $0.3345 | $0.3345 | $0.3345 | $0.3345 | 940 | 03-28-2024 |
$0.31825 | $0.3233 | $0.31825 | $0.3233 | $0.31825 | 750 | 03-27-2024 |
$0.3233 | $0.32465 | $0.3233 | $0.32465 | $0.318925 | 11,075 | 03-26-2024 |
$0.31 | $0.3146 | $0.31 | $0.3342 | $0.31 | 52,076 | 03-22-2024 |
$0.3146 | $0.3057 | $0.3146 | $0.3146 | $0.3057 | 21,936 | 03-21-2024 |
$0.3057 | $0.3116 | $0.3057 | $0.3116 | $0.3057 | 45,159 | 03-20-2024 |
$0.30665 | $0.3254 | $0.30665 | $0.3254 | $0.302 | 49,842 | 03-19-2024 |
$0.3204 | $0.316225 | $0.3204 | $0.3204 | $0.316225 | 1,565 | 03-18-2024 |
$0.324905 | $0.3307 | $0.324905 | $0.3307 | $0.324905 | 964 | 03-15-2024 |
$0.3337 | $0.34915 | $0.3337 | $0.350527 | $0.3337 | 44,970 | 03-14-2024 |
$0.3582 | $0.3403 | $0.3582 | $0.3582 | $0.3303 | 23,344 | 03-13-2024 |
$0.3426 | $0.34 | $0.3426 | $0.3426 | $0.34 | 10,500 | 03-12-2024 |
$0.32 | $0.351882 | $0.32 | $0.356 | $0.3114 | 12,800 | 03-11-2024 |
News, Short Squeeze, Breakout and More Instantly...
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE, OTCQX: ATBPF) announced that its previously announced application for an Initial Order under the Companies' Creditors Arrangement Act (the " CCAA "), has been granted by the Ontario Sup...
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE, OTCQX: ATBPF) announced that it intends to file an application today with the Ontario Superior Court of Justice (Commercial List) (the " Court ") for an Initial Order under the Companies'...
Antibe Therapeutics Inc. (“Antibe” or the “Company” TSX: ATE, OTCQX: ATBPF) today announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug Administration (“FDA”) that otenaproxesul has been placed on clinical...